Antidepressant treatment restores brain-derived neurotrophic factor serum levels and ameliorates motor function in parkinson disease patients

Journal of Clinical Psychopharmacology

Volumn 30, Issue 6, 2010, Pages 751-753

  Ricci, Valerio ^a   Pomponi, Massimiliano ^a   Martinotti, Giovanni ^a   Bentivoglio, Annarita ^a   Loria, Giovanna ^a   Bernardini, Sergio ^b   Caltagirone, Carlo ^a   Bria, Pietro ^a   Angelucci, Francesco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; BIPERIDEN; BRAIN DERIVED NEUROTROPHIC FACTOR; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PAROXETINE; PRAMIPEXOLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GENDER; HAMILTON SCALE; HUMAN; LETTER; MALE; MENTAL FUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; DEPRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MALE; PARKINSON DISEASE; SEROTONIN UPTAKE INHIBITORS;

EID: 78649357002     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181fc2ec7     Document Type: Letter

References (20)

1. Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev. 1998;27:1-39.
2. Castrén E. Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection. Mol Neurobiol. 2004;29:289-302.
3. Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell lineYderived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:1130-1132.
4. Cantello R, Aguggia M, Gilli M, et al. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the Bhedonic[ dopamine synapse. J Neurol Neurosurg Psychiatry. 1989;52:724-731.
5. Malberg JE, Eisch AJ, Nestler EJ, et al Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20:9104-9110.
6. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:7539-7547.
7. Shirayama Y, Chen AC, Nakagawa S, et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 2002;22:3251-3261.
8. Castro LM, Gallant M, Niles LP. Novel targets for valproic acid: upregulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J Neurochem. 2005;95:1227-1236.
9. Angelucci F, Aloe L, Jimenez-Vasquez P, et al. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell lineYderived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol. 2003;6: 225-231.
10. Chen B, Dowlatshahi D, MacQueen GM, et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260-265.
11. Michel TM, Frangou S, Camara S, et al. Altered glial cell lineYderived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: a comparative post-mortem study. Eur Psychiatry. 2008;23:413-420.
12. Rizos EN, Papadopoulou A, Laskos E, et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry. 2010;11:251-255.
13. Howells DW, Porritt MJ, Wong JY, et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol. 2000;166:127-135.
14. Castrén E, Rantamäki T. Role of brain-derived neurotrophic factor in the aetiology of depression: implications for pharmacological treatment. CNS Drugs. 2010;2:1-7.
15. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008;11: 1169-1180.
16. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894-902.
17. Scatton B, Javoy-Agid F, Rouquier L, et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 1983;275:321-328.
18. Chen CP, Alder JT, Bray L, et al. Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann N Y Acad Sci. 1998;861:288-289.
19. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253: 601-607.
20. Gyárfás T, Knuuttila J, Lindholm P, et al. Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cell Mol Neurobiol. 2010;30: 361-368.